ArticleArthritis research & therapy2025
Inflammation-related proteomics of extracellular vesicles as novel biomarkers for systemic lupus erythematosus revealed by proximity extension assay.
Article in Arthritis research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundSystemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by dysregulated inflammatory response lacking reliable diagnosis biomarkers and therapy targets. Extracellular vesicles (EVs)-derived cargo as biomarkers and mediators of SLE have garnered significant attention, however, quantitative inflammatory protein profile of SLE EVs remain uncovered.
objectiveCurrent study focuses on exploring the inflammatory protein landscape of SLE serum EVs via quantitative proximity extension assay (PEA) and evaluates their diagnostic utility for SLE and lupus nephritis (LN).
methodsIn this cross-sectional study, we first utilized PEA to profile inflammatory proteins derived from serum EVs in 101 individuals, including 70 SLE patients and 33 healthy controls (HCs). Subsequently, candidate EV proteins identified from this analysis were subsequently validated via ELISA in an independent cohort comprising 54 SLE patients and 58 HCs. Furthermore, machine-learning classification was utilized to generate prediction models for SLE diagnosis and LN discrimination. Finally, correlation analysis was applied to evaluate the association between EV-derived inflammatory proteins and clinical parameters.
resultsIn the sEV PEA discovery cohort, a total of 49 significantly dysregulated inflammatory proteins with 43 elevated proteins were identified in serum EVs from SLE patients. Two precision prediction models were generated using the random Forest algorithm (RF) for SLE identification and LN discrimination, achieving AUCs of 0.999 and 0.793, respectively. Multiple EV proteins such as CCL23, IL-18R1, SCF and CSF-1 showed a significant correlation with SLE severity parameters including SLEDAI, eGFR and UACR. Furthermore, representative EV proteins including IL-18R1, CCL23 and IFN-γ were further tested in the sEV ELISA validation cohort including 54 SLE patients and 58 HCs.
conclusionsThe present study identified a unique pattern EV-derived inflammatory proteins in patients with SLE, which could serve as novel biomarkers for SLE diagnosis and disease monitoring.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.